GFAP and Cognitive impairment: Blood GFAP levels can predict not only AD development in patients with mild cognitive impairment but also cognitive decline in cognitively unimpaired subjects (Verberk et al., 2020; Cicognola et al., 2021; Verberk et al., 2021).